A five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors, showing how concentrated real-world evidence generation for HR+/HER2- mBC actually is.
The UK's HR+/HER2- metastatic breast cancer KOL universe is not evenly distributed across the country. A real-world evidence consortium spanning five South West England centres, Bristol, Bath, Taunton, Cheltenham, and Exeter, tracked 666 patients across all three NICE-approved CDK4/6 inhibitors: 537 on palbociclib, 85 on abemaciclib, and 44 on ribociclib. That kind of coordinated, multi-centre data generation does not happen by accident. It signals a KOL network structured around shared trial participation and joint publication, not isolated individual practices. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence. A KOL who co-authors a five-centre consortium's real-world evidence paper carries a different kind of scientific weight than one working in isolation, and our Tier Classification gate (K2) scores that distinction directly, alongside NICE technology appraisal stakeholder submissions and ABC/ESMO guideline-committee roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live trial registries, publication records, and guideline documentation, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over prescribing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The South West England real-world evidence consortium — UK CDK4/6 inhibitor cohort
| Agent | UK Patients (Consortium Cohort) | Share | 1L Median PFS |
|---|---|---|---|
| Palbociclib | 537 | 80.6% | 31 months (25–35) |
| Abemaciclib | 85 | 12.8% | 16 months (9–NR) |
| Ribociclib | 44 | 6.6% | 44 months (21–NR) |
Sources: Gullick G et al., UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer, ESMO Real World Data & Digital Oncology, 2024; NICE TA836 (palbociclib plus fulvestrant).
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The South West England five-centre consortium structure
- institutional concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- NICE TA stakeholder submission and ABC/ESMO guideline-role weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live trial-registry and publication cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the South West England consortium case before the rest of the workbook is built out
- Every UK HR+/HER2- mBC KOL sized and sourced from trial-registry, consortium, and publication data
- The South West England five-centre network as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across consortium membership, NICE stakeholder roles, and guideline authorship
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: trial leadership, NICE TA stakeholder submissions, ABC/ESMO guideline roles
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map against the South West England network and the rest of the UK
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond the UK, EU congress roles, ABC international consensus
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live trial registries, publication records, and guideline documentation, not secondary summaries. No KOL name ships without a verification tag.
UK HR+/HER2- mBC KOL sources: the South West England real-world evidence consortium (Gullick et al., ESMO Real World Data & Digital Oncology 2024), NICE technology appraisal documentation (TA836 and related CDK4/6 inhibitor appraisals), and ABC/ESMO guideline-committee records.
- Consortium patient counts and PFS figures verified against Gullick et al. (ESMO Real World Data & Digital Oncology, 2024)
- NICE TA836 (palbociclib plus fulvestrant) verified against the live NICE guidance page
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK HR+/HER2- mBC specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.